Cover Image
Market Research Report

Alnylam Pharmaceuticals, Inc. - Product Pipeline Review - 2016

Published by Global Markets Direct Product code 224581
Published Content info 88 Pages
Delivery time: 1-2 business days
Price
Back to Top
Alnylam Pharmaceuticals, Inc. - Product Pipeline Review - 2016
Published: July 27, 2016 Content info: 88 Pages
Description

Summary:

Global Markets Direct's, 'Alnylam Pharmaceuticals, Inc. - Product Pipeline Review, 2016', provides an overview of the Alnylam Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Alnylam Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the pipeline therapeutic landscape of Alnylam Pharmaceuticals, Inc.
  • The report provides overview of Alnylam Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Alnylam Pharmaceuticals, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Alnylam Pharmaceuticals, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy:

  • Evaluate Alnylam Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Alnylam Pharmaceuticals, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Alnylam Pharmaceuticals, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Product Code: GMDHC08097CDB

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Alnylam Pharmaceuticals, Inc. Snapshot
    • Alnylam Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Alnylam Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Alnylam Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Alnylam Pharmaceuticals, Inc. - Pipeline Products Glance
    • Alnylam Pharmaceuticals, Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Alnylam Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Alnylam Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Alnylam Pharmaceuticals, Inc. - Drug Profiles
    • patisiran
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • revusiran
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-PCSsc
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • fitusiran
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-AAT
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-CC5
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-GO1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-HBV
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-AS1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-TTRsc02
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-VSP
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-AC3
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-AGT
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-ANG
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-PDL
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-TMP
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense RNAi Oligonucleotide to Target Cyclin-Dependent Kinase Inhibitor 1 for Bladder Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy for Oncology and Viral Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-HDV
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RNAi Oligonucleotide for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RNAi Oligonucleotides for Genetic Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RNAi Oligonucleotides for Hepatic Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RNAi Oligonucleotides for NASH, Cardiovascular and Metabolic Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Alnylam Pharmaceuticals, Inc. - Pipeline Analysis
    • Alnylam Pharmaceuticals, Inc. - Pipeline Products by Target
    • Alnylam Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Alnylam Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Alnylam Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Alnylam Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Alnylam Pharmaceuticals, Inc. - Dormant Projects
  • Alnylam Pharmaceuticals, Inc. - Company Statement
  • Alnylam Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Alnylam Pharmaceuticals, Inc., Key Information
  • Alnylam Pharmaceuticals, Inc., Key Facts
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Indication, 2016
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
  • Alnylam Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
  • Alnylam Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2016
  • Alnylam Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2016
  • Alnylam Pharmaceuticals, Inc. - Phase III, 2016
  • Alnylam Pharmaceuticals, Inc. - Phase II, 2016
  • Alnylam Pharmaceuticals, Inc. - Phase I, 2016
  • Alnylam Pharmaceuticals, Inc. - Preclinical, 2016
  • Alnylam Pharmaceuticals, Inc. - Discovery, 2016
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Target, 2016
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
  • Alnylam Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016
  • Alnylam Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016
  • Alnylam Pharmaceuticals, Inc. - Dormant Developmental Projects,2016
  • Alnylam Pharmaceuticals, Inc., Subsidiaries

List of Figures

  • Alnylam Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2016
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
  • Alnylam Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2016
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
  • Alnylam Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top